研究者詳細 - 平沢　晃

論文 - 平沢　晃

分割表示 403 件中 301 - 320 件目／全件表示 >>

Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer

Makiko Kawaguchi, Megumi Yanokura, Kouji Banno, Yusuke Kobayashi, Yoshiko Kuwabara, Maya Kobayashi, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Datsuke Aoki

INTERNATIONAL JOURNAL OF ONCOLOGY 34 ( 6 ) 1541 - 1547 2009年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPANDIDOS PUBL LTD

Point mutations of KRAS and BRAF genes are thought to be important in carcinogenesis of colon cancer. In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch repair (MMR) gene, may be linked to the activating BRAF V600E point mutation in sporadic colon cancer. However, a consensus has not been established regarding the correlation between point mutations of KRAS or BRAF and carcinogenesis in patients with endometrial cancer, which is closely related to colon cancer. Therefore, we analyzed aberrant hypermethylation of the hMLH1 gene, microsatellite instability (MSI), and point mutations of KRAS and BRAF in 44 samples of sporadic endometrial cancer, with the aim of examining the mechanism of carcinogenesis in patients with endometrial cancer. Aberrant hMLH1 hypermethylation was found in 17 of the 44 cases (38.6%) and showed a significant positive correlation with MSI (p=0.02). This suggests that an abnormal MMR mechanism plays an important role in carcinogenesis of sporadic endometrial cancer. Point mutation of KRAS was found in 6 of the 44 cases (13.6%), but no BRAF V600E mutation was detected. These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinogenesis in patients with sporadic endometrial cancer, unlike in colon cancer. This is supported by the relatively few previous reports indicating a correlation between endometrial cancer and the BRAF V600E mutation. Identification of new candidates for the target gene for abnormal MMR in endometrial cancer requires further work.

DOI： 10.3892/ijo_00000283

Endometrial cancer as HNPCC associated tumor

青木大輔

家族性腫瘍 9 ( 2 ) 64-68 2009年5月

Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review) 査読

Kouji Banno, Megumi Yanokura, Yusuke Kobayashi, Makiko Kawaguchi, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Daisuke Aoki

CURRENT GENOMICS 10 ( 2 ) 127 - 132 2009年4月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BENTHAM SCIENCE PUBL LTD

Some cases of endometrial cancer are associated with a familial tumor and are referred to as hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome). Such tumors are thought to be induced by germline mutation of the DNA mismatch repair (MMR) gene, but many aspects of the pathology of familial endometrial cancer are unclear and no effective screening method has been established. However, the pathology of endometrial cancer with familial tumor has been progressively clarified in recent studies. At present, about 0.5% of all cases of endometrial cancers meet the clinical diagnostic criteria for HNPCC. A recent analysis of the three MMR genes (hMLH1, hMSH2 and hMSH6) revealed germline mutations in 18 of 120 cases (15.0%) of endometrial cancer with familial accumulation of cancer or double cancer, with a frameshift mutation of the hMSH6 gene being the most common. Many cases with mutation did not meet the current clinical diagnostic criteria for HNPCC, indicating that familial endometrial cancer is often not diagnosed as HNPCC. The results suggest that the hMSH6 gene mutation may be important in carcinogenesis in endometrial cancer and germline mutations of the MMR gene may be more prevalent in cases associated with familial accumulation of cancer. An international large-scale muticenter study is required to obtain further information about the pathology of endometrial cancer as a familial tumor.

DOI： 10.2174/138920209787847069

結合型エストロゲン製剤を用いたホルモン補充療法の腰椎骨密度に対する長期的な効果の検討～当科更年期外来における継続投与10年例の結果から～

牧田和也, 堀場裕子, 平沢晃, 岩田卓, 冨永英一郎, 堀口文, 青木大輔

Osteoporosis Japan 17 ( 2 ) 329-330 - 330 2009年4月

Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis (review). 国際誌

Kouji Banno, Megumi Yanokura, Yusuke Kobayashi, Makiko Kawaguchi, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Daisuke Aoki

Current genomics 10 ( 2 ) 127 - 32 2009年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Some cases of endometrial cancer are associated with a familial tumor and are referred to as hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome). Such tumors are thought to be induced by germline mutation of the DNA mismatch repair (MMR) gene, but many aspects of the pathology of familial endometrial cancer are unclear and no effective screening method has been established. However, the pathology of endometrial cancer with familial tumor has been progressively clarified in recent studies. At present, about 0.5% of all cases of endometrial cancers meet the clinical diagnostic criteria for HNPCC. A recent analysis of the three MMR genes (hMLH1, hMSH2 and hMSH6) revealed germline mutations in 18 of 120 cases (15.0%) of endometrial cancer with familial accumulation of cancer or double cancer, with a frameshift mutation of the hMSH6 gene being the most common. Many cases with mutation did not meet the current clinical diagnostic criteria for HNPCC, indicating that familial endometrial cancer is often not diagnosed as HNPCC. The results suggest that the hMSH6 gene mutation may be important in carcinogenesis in endometrial cancer and germline mutations of the MMR gene may be more prevalent in cases associated with familial accumulation of cancer. An international large-scale muticenter study is required to obtain further information about the pathology of endometrial cancer as a familial tumor.

DOI： 10.2174/138920209787847069

当科更年期外来における更年期不定愁訴に対する漢方薬の使用状況について-8年前の調査結果との比較検討-.

牧田和也, 堀場裕子, 平沢晃, 岩田卓, 片岡史夫, 冨永英一郎, 堀口文, 青木大輔, 吉村泰典

産婦人科漢方研究のあゆみ 26 ( 26 ) 44-47 - 47 2009年

記述言語：日本語出版者・発行元：産婦人科漢方研究会

2006年1月〜2007年12月に更年期外来を3ヵ月以上継続通院した671例を抽出し、治療内容について外来カルテを中心に追跡調査し、2000年外来で行った同様調査結果と比較検討した。125例(18.6%)は特に継続的な薬物治療は行わず、血液検査や骨密度測定を定期的に施行している経過観察例、残り546例(81.4%)は継続的な薬物治療が行われていた。ホルモン補充療法(HRT)継続施行例は128例(19.1%)、漢方薬のみ使用例は54例(8.5%)であった。漢方薬の内訳は8年前の調査では桂枝茯苓丸の使用頻度が最も高く、加味逍遙散、牛車腎気丸、芍薬甘草湯の順であったが、今回調査でも使用頻度は桂枝茯苓丸が最も高く、以下加味逍遙散と共に慢性頭痛に対する呉茱萸湯、釣藤散使用例が急増していた。8年前調査では使用漢方薬の種類は10種類程度であったが今回調査では23種類に及んでいた。

更年期外来受診患者における動脈硬化性疾患の危険因子に関する検討.

柳本茂久, 牧田和也, 堀場裕子, 平沢晃, 高松潔, 堀口文, 青木大輔

日本更年期医学会雑誌 17 ( 2 ) 171-178 - 178 2009年

記述言語：日本語出版者・発行元：(一社)日本女性医学学会

日本動脈硬化学会の「動脈硬化性疾患の予防と治療に関するガイドライン」が5年ぶりに改定され、その中で「高脂血症」の疾患名は「脂質異常症」に改められている。2007年10月〜2008年12月に更年期外来に受診した初診患者199例(平均54.7歳)を対象として、新しいガイドラインに基づく動脈硬化性疾患の一次予防に関連する危険因子について検証した。199例中87例(43.7%)が「脂質異常症」の診断基準を満たし、79例(39.7%)は評価対象となる危険因子を認めず、1項目該当が76例(38.2%)、2項目該当が24例(12.1%)、3項目以上該当が20例(10.1%)であった。危険因子別では年齢が最も多く該当し、次いで両親の心筋梗塞/狭心症の既往と高血圧が多く認められた。更年期外来受診者においては、動脈硬化性疾患の危険因子として55歳以上という年齢因子を有する者が最も多く、保有因子数が0〜1個の低〜中リスク群に分類される者が主であることが判明した。

Endometrial cancer as a familial tumor: Pathology and molecular carcinogenesis (review)

Kouji Banno, Megumi Yanokura, Yusuke Kobayashi, Makiko Kawaguchi, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu, Daisuke Aoki

Current Genomics 10 ( 2 ) 127 - 132 2009年

記述言語：英語

Some cases of endometrial cancer are associated with a familial tumor and are referred to as hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome). Such tumors are thought to be induced by germline mutation of the DNA mismatch repair (MMR) gene, but many aspects of the pathology of familial endometrial cancer are unclear and no effective screening method has been established. However, the pathology of endometrial cancer with familial tumor has been progressively clarified in recent studies. At present, about 0.5% of all cases of endometrial cancers meet the clinical diagnostic criteria for HNPCC. A recent analysis of the three MMR genes (hMLH1, hMSH2 and hMSH6) revealed germline mutations in 18 of 120 cases (15.0%) of endometrial cancer with familial accumulation of cancer or double cancer, with a frameshift mutation of the hMSH6 gene being the most common. Many cases with mutation did not meet the current clinical diagnostic criteria for HNPCC, indicating that familial endometrial cancer is often not diagnosed as HNPCC. The results suggest that the hMSH6 gene mutation may be important in carcinogenesis in endometrial cancer and germline mutations of the MMR gene may be more prevalent in cases associated with familial accumulation of cancer. An international large-scale muticenter study is required to obtain further information about the pathology of endometrial cancer as a familial tumor. © 2009 Bentham Science Publishers Ltd.

DOI： 10.2174/138920209787847069

閉経後骨粗鬆症に対する予防的治療を行う際の薬剤選択に関する再検証.

牧田和也, 平沢晃, 堀場裕子, 弟子丸亮太, 柳本茂久, 堀口文, 青木大輔

Osteoporosis Japan 17 ( 3 ) 447-449 - 449 2009年

記述言語：日本語出版者・発行元：ライフサイエンス出版(株)

過去10年間に更年期外来で腰椎骨密度値から「原発性骨粗鬆症」と診断された106症例、「骨量減少」と診断された183症例、および少なくとも1年以上骨粗鬆症に対する治療を施行している塩酸ラロキシフェン(RLX)投与群35症例と各種ビスフォスフォネート(BIS)投与群43症例を対象に、薬剤選択について再検証した。その結果、1)骨粗鬆症例では骨量減少例や骨密度正常範囲例と比べて、診断時の年齢が有意に高く、閉経ないし卵巣全摘出後期間が有意に長い傾向にあった。2)骨量減少例は骨粗鬆症例と比較して、閉経後5年未満ないし周閉経期が多く、血管運動神経症状を合併した症例も少なくなかった。3)RLX群はBIS群と比べて薬剤開始年齢が有意に高いが、その施行期間が発売開始時期の差異を反映して有意に短い傾向にあった。3)RLXが初回治療薬となっていたのは35例中10例で、21例は2種類以上の薬剤治療歴が認められた。尚、ホルモン補充療法からの直接の切替えは4例であった。

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J03021&link_issn=&doc_id=20090813170015&doc_link_id=%2Fai6ostoe%2F2009%2F001703%2F016%2F0447-0449%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fai6ostoe%2F2009%2F001703%2F016%2F0447-0449%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

子宮体がん例におけるFRAXを用いた骨折リスク評価.

平沢晃, 牧田和也, 堀場裕子, 弟子丸亮太, 柳本茂久, 阪埜浩司, 進伸幸, 青木大輔

Osteoporosis Japan 17 ( 3 ) 492-495 - 495 2009年

記述言語：日本語出版者・発行元：ライフサイエンス出版(株)

FRAX(fracture risk assessment tool)は将来的な大腿骨近位部骨折リスクを判定するスコアとして汎用されているが、閉経前の卵巣摘出が骨粗鬆症の危険因子であるにもかかわらず、その調査項目に含まれていない。そこで、子宮体癌例におけるFRAXを用いた骨折リスク評価の特徴を検討した。対象は両側卵巣摘出術を伴う手術療法を施行した子宮体癌症例112例(平均年齢58歳)で、健康維持外来通院中の非子宮体癌132例(平均年齢53歳)を対照とした。その結果、1)子宮体癌群ではBMI高値例が有意に多く、子宮体癌の罹患の有無にかかわらず、10年以内の大腿骨近位部骨折の発生リスクが10%以上の高危険例は高齢者に多かった。2)本検討により、大腿骨近位部骨折のリスクに影響を及ぼす因子として、FRAXに含まれる危険因子よりもそれ以外の環境因子や遺伝的因子等が関与する可能性も示唆された。

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J03021&link_issn=&doc_id=20090813170027&doc_link_id=%2Fai6ostoe%2F2009%2F001703%2F028%2F0492-0495%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fai6ostoe%2F2009%2F001703%2F028%2F0492-0495%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

当科更年期外来における塩酸ラロキシフェン治療の現況-子宮体癌術後症例を中心に-.

牧田和也, 堀場裕子, 岩田卓, 平沢晃, 片岡史夫, 富永英一郎, 堀口文, 青木大輔

SERM 7 106-107 2009年

Can ABCF2 protein expression predict the prognosis of uterine cancer? 査読

S. Nishimura, H. Tsuda, Y. Miyagi, A. Hirasawa, A. Suzuki, F. Kataoka, H. Nomura, T. Chiyoda, K. Banno, T. Fujii, N. Susumu, D. Aoki

BRITISH JOURNAL OF CANCER 99 ( 10 ) 1651 - 1655 2008年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：NATURE PUBLISHING GROUP

Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity ( risk ratio (rr) = 1.437), old age (rr = 1.550) and advanced stage (rr = 2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

DOI： 10.1038/sj.bjc.6604734

Can ABCF2 protein expression predict the prognosis of uterine cancer?

S. Nishimura, H. Tsuda, Y. Miyagi, A. Hirasawa, A. Suzuki, F. Kataoka, H. Nomura, T. Chiyoda, K. Banno, T. Fujii, N. Susumu, D. Aoki

BRITISH JOURNAL OF CANCER 99 ( 10 ) 1651 - 1655 2008年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：NATURE PUBLISHING GROUP

Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity ( risk ratio (rr) = 1.437), old age (rr = 1.550) and advanced stage (rr = 2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

DOI： 10.1038/sj.bjc.6604734

子宮がん患者へのインフォームドコンセント（IC）

進伸幸, 平沢晃, 阪埜浩司, 藤井多久磨, 青木大輔

臨床腫瘍プラクティス 4 ( 4 ) 313-319 - 319 2008年11月

記述言語：日本語出版者・発行元：(株)ヴァンメディカル

＜View Points＞がん告知は十分な組織学的根拠が得られてから慎重に行う。がん告知は患者と家族が同席する場で行い、診療録にその説明内容を記載する。特に妊孕性温存の可否、妊娠中の子宮頸がん発症時の妊娠継続の可否、卵巣機能温存の可否などの説明には、詳細なevidenceの説明、選択決定のための反復説明も必要となる場合がある。病態説明や治療法選択に関しては、口頭だけでなく書面でも情報提供を行いinformed consentを得ることが望ましい。(著者抄録)

Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. 査読国際誌

Kokichi Sugano, Seigo Nakamura, Jiro Ando, Shin Takayama, Hiroyuki Kamata, Isao Sekiguchi, Megumi Ubukata, Tetsuro Kodama, Masami Arai, Fujio Kasumi, Yasuo Hirai, Tadashi Ikeda, Hiromitsu Jinno, Masaki Kitajima, Daisuke Aoki, Akira Hirasawa, Yuko Takeda, Kumiko Yazaki, Takashi Fukutomi, Takayuki Kinoshita, Ryuichiro Tsunematsu, Teruhiko Yoshida, Masako Izumi, Shino Umezawa, Hiroshi Yagata, Hiroko Komatsu, Naoko Arimori, Noriko Matoba, Nobuhisa Gondo, Shiro Yokoyama, Yoshio Miki

Cancer science 99 ( 10 ) 1967 - 76 2008年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：WILEY-BLACKWELL

The prevalence of BRCA1/2 germline mutations in Japanese patients suspected to have hereditary breast/ovarian cancer was examined by a multi-institutional study, aiming at the clinical application of total sequencing analysis and validation of assay sensitivity in Japanese people using a cross-sectional approach based on genetic factors estimated from personal and family histories. One hundred and thirty-five subjects were referred to the genetic counseling clinics and enrolled in the study. Full sequencing analysis of the BRCA1/2 gene showed 28 types of deleterious mutations in 36 subjects (26.7%), including 13 types of BRCA1 mutations in 17 subjects (12.6%) and 15 types of BRCA2 mutations in 19 subjects (14.1%). Subjects were classified into five groups and 22 subgroups according to their personal and family history of breast and/or ovarian cancer, and the prevalence of deleterious mutations was compared with previously reported data in non-Ashkenazi individuals. Statistical analysis using the Mantel-Haenszel test for groups I through IV revealed that the prevalence of Japanese subjects was significantly higher than that of non-Ashkenazi individuals (P = 0.005, odds ratio 1.87, 95% confidence interval 1.22-2.88). Family history of the probands suffering from breast cancer indicated risk factors for the presence of deleterious mutations of BRCA1/2 as follows: (1) families with breast cancer before age 40 within second degree relatives (P = 0.0265, odds ratio 2.833, 95% confidence interval 1.165-7.136) and (2) families with bilateral breast cancer and/or ovarian cancer within second degree relatives (P = 0.0151, odds ratio 2.88, 95% confidence interval 1.25-6.64).

DOI： 10.1111/j.1349-7006.2008.00944.x

Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer

Kokichi Sugano, Seigo Nakamura, Jiro Ando, Shin Takayama, Hiroyuki Kamata, Isao Sekiguchi, Megumi Ubukata, Tetsuro Kodama, Masami Arai, Fujio Kasumi, Yasuo Hirai, Tadashi Ikeda, Hiromitsu Jinno, Masaki Kitajima, Daisuke Aoki, Akira Hirasawa, Yuko Takeda, Kumiko Yazaki, Takashi Fukutomi, Takayuki Kinoshita, Ryuichiro Tsunematsu, Teruhiko Yoshida, Masako Izumi, Shino Umezawa, Hiroshi Yagata, Hiroko Komatsu, Naoko Arimori, Noriko Matoba, Nobuhisa Gondo, Shiro Yokoyama, Yoshio Miki

CANCER SCIENCE 99 ( 10 ) 1967 - 1976 2008年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：WILEY-BLACKWELL

The prevalence of BRCA1/2 germline mutations in Japanese patients suspected to have hereditary breast/ovarian cancer was examined by a multi-institutional study, aiming at the clinical application of total sequencing analysis and validation of assay sensitivity in Japanese people using a cross-sectional approach based on genetic factors estimated from personal and family histories. One hundred and thirty-five subjects were referred to the genetic counseling clinics and enrolled in the study. Full sequencing analysis of the BRCA1/2 gene showed 28 types of deleterious mutations in 36 subjects (26.7%), including 13 types of BRCA1 mutations in 17 subjects (12.6%) and 15 types of BRCA2 mutations in 19 subjects (14.1%). Subjects were classified into five groups and 22 subgroups according to their personal and family history of breast and/or ovarian cancer, and the prevalence of deleterious mutations was compared with previously reported data in non-Ashkenazi individuals. Statistical analysis using the Mantel-Haenszel test for groups I through IV revealed that the prevalence of Japanese subjects was significantly higher than that of non-Ashkenazi individuals (P = 0.005, odds ratio 1.87, 95% confidence interval 1.22-2.88). Family history of the probands suffering from breast cancer indicated risk factors for the presence of deleterious mutations of BRCA1/2 as follows: (1) families with breast cancer before age 40 within second degree relatives (P = 0.0265, odds ratio 2.833, 95% confidence interval 1.165-7.136) and (2) families with bilateral breast cancer and/or ovarian cancer within second degree relatives (P = 0.0151, odds ratio 2.88, 95% confidence interval 1.25-6.64). (Cancer Sci 2008; 99: 1967-1976).

DOI： 10.1111/j.1349-7006.2008.00944.x

子宮体がん術後患者における骨密度の特徴に関する検討.

平沢晃, 牧田和也, 堀場裕子, 弟子丸亮太, 柳本茂久, 野村弘行, 片岡史夫, 岩田卓, 冨永英一郎, 阪埜浩司, 進伸幸, 堀口文, 青木大輔

Osteoporosis Japan 16 ( 3 ) 429-431 2008年

季節による漢方製剤の切り替えが片頭痛発作の軽減に有効であった1例.

牧田和也, 平沢晃, 冨永英一郎, 堀口文, 青木大輔, 吉村泰典

産婦人科漢方研究のあゆみ 25 ( 25 ) 115-118 - 118 2008年

記述言語：日本語出版者・発行元：産婦人科漢方研究会

症例は初診時48歳で、閉経に伴い片頭痛発作が再燃・増悪した。季節によって東洋医学的病態が異なることに着目し、使用する漢方製剤の切り替えを行った。すなわち、「水毒」の徴候がみられる春〜夏季には五苓散、「冷え」がみられる秋〜冬季には当帰四逆加呉茱萸生姜湯を使用し、良好な経過が得られている。

当科更年期外来にて診断し得た骨粗鬆症/骨量減少症における低エストロゲン血症以外の危険因子の検討.

牧田和也, 冨永英一郎, 平沢晃, 堀口文, 青木大輔

Osteoporosis Japan 16 ( 2 ) 308 - 308 2008年

当科更年期外来受診者におけるアレンドロネート製剤のweekly投与への切り替えの現状.

牧田和也, 平沢晃, 冨永英一郎, 堀口文, 青木大輔

Osteoporosis Japan 16 ( 3 ) 268-269 - 469 2008年

記述言語：日本語出版者・発行元：ライフサイエンス出版(株)

更年期外来で閉経後骨粗鬆症又は骨量減少と診断され、薬物治療を1年以上継続し、2006年度アンケートに協力した57例(平均61.3歳)を対象にアレンドロネート製剤の2007年10月以降の外来受診者切替えの現状について報告した。07年10月以降15例中13例が移行したが、2例は従来からの連日服用のままで大きな問題はないとして移行しなかった。リセドロネート製剤の07年10月の服用状況は12例中3例が1年以内に脱落・移行し、7例は従来通り連日服用を継続した。エチドロネート製剤の07年10月の服用状況は18例中2例が1年以内に脱落、1例が上腹部痛の副作用のためビタミンD3(VD3)製剤に2例が骨密度に対する治療効果不良でアレンドロネート製剤へ移行、残り10例がその後も継続服用した。ラロキシフェンの07年10月の服用状況は12例中1例が副作用でVD3製剤に、1例がアレンドロネート製剤に、残り10例が継続した。

　前のページ - 次のページ　

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21